Multimodal Platform Fluxergy is building a single platform that consolidates molecular, chemistry, immunochemistry and cytometry tests, enabling point-of-care testing with automated, sample-to-answer workflows. This presents a sales opportunity to position Fluxergy as a scalable solution for clinics, veterinary labs and hospitals seeking to replace multiple benchtop systems with one integrated analyzer, reducing capital and maintenance costs.

In-house PCR Growth The company launched an in-house PCR platform and has achieved adoption in over 80 veterinary labs and referral hospitals across US, Canada and EU. This indicates a ready-made reference base and proven demand for PCR-based diagnostics, suggesting expansion opportunities into broader veterinary networks and cross-selling companion molecular assays.

Strategic Partnerships Recent collaboration with NIH NIAID signals credibility and potential access to public-sector or grant-funded projects. Sales efforts can target government and research institutions, highlighting Fluxergy’s platform as capable of supporting large-scale infectious disease testing programs and research initiatives.

Clinical and Vet Focus Participation in clinical lab expos and veterinary diagnostics conferences, plus a diversified product roadmap covering human and veterinary testing, positions Fluxergy to pursue dual-market growth. Targeted outreach to hospital systems, reference laboratories and veterinary networks can drive multi-domain deployments and cross-market expansion.

European and US Footprint Active presence in North America and EU with commercial rollout in veterinary labs suggests a balanced geographic footprint and potential for regional channel partnerships, local regulatory navigation, and pilot programs to accelerate adoption in new markets.